title: Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects.
abstract: This randomized, double-blind, placebo-controlled study evaluated the pharmacodynamic effects of concomitant low-dose aspirin and lumiracoxib in healthy subjects. Participants received lumiracoxib 400 mg once daily (n = 14) or placebo (n = 14) for 11 days, with concomitant low-dose aspirin (75 mg once daily) from days 5 to 11. Ex vivo pharmacodynamic assessments included assays of platelet aggregation and urinary thromboxane and prostacyclin metabolite profile. Arachidonic acid-stimulated platelet aggregation was reduced from 76.3% on day 4 to 4.8% on day 11 in the placebo group and from 75.8% on day 4 to 5.1% on day 11 in the lumiracoxib group. Collagen-induced platelet aggregation was reduced from 77.5% on day 4 to 52.8% on day 11 in the placebo group and from 79.5% on day 4 to 55.9% on day 11 in the lumiracoxib group. Urinary thromboxane and prostacyclin were unaffected by lumiracoxib. In conclusion, concomitant lumiracoxib did not interfere with the cyclooxygenase-1-mediated antiplatelet effects of low-dose aspirin.
authors.affiliation: Exploratory Clinical Development, Novartis Pharma AG, WSJ-103-4 D, CH-4002 Basel, Switzerland.
authors.forename: J
authors.initials: J
authors.lastname: Jermany
authors.forename: J
authors.initials: J
authors.lastname: Branson
authors.forename: R
authors.initials: R
authors.lastname: Schmouder
authors.forename: M
authors.initials: M
authors.lastname: Guillaume
authors.forename: C
authors.initials: C
authors.lastname: Rordorf
mesh_terms: D000293:Adolescent; D000328:Adult; D016718:Arachidonic Acid / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology*; D003094:Collagen / Q000494:pharmacology; D051545:Cyclooxygenase 1 / Q000378:metabolism; D051546:Cyclooxygenase 2 / Q000378:metabolism; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004008:Diclofenac / Q000031:analogs & derivatives; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004347:Drug Interactions; D011464:Epoprostenol / Q000652:urine; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009930:Organic Chemicals / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D013929:Thromboxane B2 / Q000097:blood / Q000652:urine
chemical_list: D016861:Cyclooxygenase Inhibitors; D009930:Organic Chemicals; D010975:Platelet Aggregation Inhibitors; D004008:Diclofenac; D016718:Arachidonic Acid; D013929:Thromboxane B2; D003094:Collagen; D011464:Epoprostenol; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D001241:Aspirin; C473384:lumiracoxib